Is Argireline with Matrixyl and SNAP-8 legal in the United Kingdom?

The standard three-peptide face serum. One component has a randomised placebo-controlled trial in 60 people; the other two have trade names rather than trials. The percentage on the bottle almost never describes the peptide, because these ingredients are sold to formulators as dilute supplier solutions, so a serum labelled with a peptide percentage usually contains a fraction of that in actual peptide.

This is the most widely sold blend in this database by unit volume and the one where the label is least likely to mean what a buyer thinks. Start with what has been tested.

Mechanism: Argireline is claimed to interfere with SNARE complex formation and catecholamine release, the topical analogue of what botulinum toxin does by injection, at a fraction of the potency. The palmitoyl peptides in the Matrixyl family are matrikines claimed to signal fibroblasts to produce collagen.

Regulatory history: Cosmetic ingredients, not drugs. Cosmetic products are not subject to premarket approval in the United States, and claims that a product changes the structure or function of skin would make it a drug claim.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Argireline with Matrixyl and SNAP-8 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.